Similar articles for PMID: 31200827

Year	Number of Results
2015	1
2016	4
2017	9
2018	27
2019	37
2020	30
2021	29
2022	14
2023	4
2024	0

1

Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies.

Solassol J, Vendrell JA, Senal R, Audran P, Leenhardt F, Quantin X. Solassol J, et al. Lung Cancer. 2019 Jul;133:45-47. doi: 10.1016/j.lungcan.2019.05.003. Epub 2019 May 4. Lung Cancer. 2019. PMID: 31200827

2

Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.

Knebel FH, Bettoni F, Shimada AK, Cruz M, Alessi JV, Negrão MV, Reis LFL, Katz A, Camargo AA. Knebel FH, et al. Lung Cancer. 2017 Jun;108:238-241. doi: 10.1016/j.lungcan.2017.04.004. Epub 2017 Apr 10. Lung Cancer. 2017. PMID: 28625643

3

From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.

Bordi P, Del Re M, Minari R, Rofi E, Buti S, Restante G, Squadrilli A, Crucitta S, Casartelli C, Gnetti L, Azzoni C, Bottarelli L, Petrini I, Cosenza A, Ferri L, Rapacchi E, Danesi R, Tiseo M. Bordi P, et al. Lung Cancer. 2019 May;131:78-85. doi: 10.1016/j.lungcan.2019.03.017. Epub 2019 Mar 19. Lung Cancer. 2019. PMID: 31027702 Clinical Trial.

4

Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.

Meng P, Koopman B, Kok K, Ter Elst A, Schuuring E, van Kempen LC, Timens W, Hiltermann TJN, Groen HJM, van den Berg A, van der Wekken AJ. Meng P, et al. Lung Cancer. 2020 Aug;146:358-361. doi: 10.1016/j.lungcan.2020.05.036. Epub 2020 Jun 4. Lung Cancer. 2020. PMID: 32534795 Free article.

5

Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.

Takahama T, Azuma K, Shimokawa M, Takeda M, Ishii H, Kato T, Saito H, Daga H, Tsuboguchi Y, Okamoto I, Otsubo K, Akamatsu H, Teraoka S, Takahashi T, Ono A, Ohira T, Yokoyama T, Sakai K, Yamamoto N, Nishio K, Nakagawa K. Takahama T, et al. Cancer. 2020 Jan 1;126(9):1940-1948. doi: 10.1002/cncr.32749. Epub 2020 Feb 5. Cancer. 2020. PMID: 32022929 Free article. Clinical Trial.

6

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.

Minari R, Bordi P, Del Re M, Facchinetti F, Mazzoni F, Barbieri F, Camerini A, Comin CE, Gnetti L, Azzoni C, Nizzoli R, Bortesi B, Rofi E, Petreni P, Campanini N, Rossi G, Danesi R, Tiseo M. Minari R, et al. Lung Cancer. 2018 Jan;115:21-27. doi: 10.1016/j.lungcan.2017.11.011. Epub 2017 Nov 13. Lung Cancer. 2018. PMID: 29290257

7

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.

Hochmair MJ, Buder A, Schwab S, Burghuber OC, Prosch H, Hilbe W, Cseh A, Fritz R, Filipits M. Hochmair MJ, et al. Target Oncol. 2019 Feb;14(1):75-83. doi: 10.1007/s11523-018-0612-z. Target Oncol. 2019. PMID: 30539501 Free PMC article. Clinical Trial.

8

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.

Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu VW, Albacker L, Stephens PJ, Miller VA, Ali SM. Ou SI, et al. Lung Cancer. 2017 Jun;108:228-231. doi: 10.1016/j.lungcan.2017.04.003. Epub 2017 Apr 12. Lung Cancer. 2017. PMID: 28625641 Free article.

9

Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.

La Monica S, Minari R, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Galetti M, Digiacomo G, Riccardi F, Petronini PG, Tiseo M, Alfieri R. La Monica S, et al. Target Oncol. 2019 Oct;14(5):619-626. doi: 10.1007/s11523-019-00669-x. Target Oncol. 2019. PMID: 31502118

10

The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.

O'Kane GM, Liu G, Stockley TL, Shabir M, Zhang T, Law JH, Le LW, Sacher A, Shepherd FA, Bradbury PA, Leighl NB. O'Kane GM, et al. Lung Cancer. 2019 May;131:86-89. doi: 10.1016/j.lungcan.2019.03.019. Epub 2019 Mar 20. Lung Cancer. 2019. PMID: 31027703

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

129 results

Results by year